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Abstract
Background: Costs of tuberculosis diagnosis and treatment may represent a significant burden for the poor and for the
health system in resource-poor countries.
Objectives: The aim of this study was to analyze patients’ costs of tuberculosis care and to estimate the incremental cost-
effectiveness ratio (ICER) of the directly observed treatment (DOT) strategy per completed treatment in Rio de Janeiro,
Brazil.
Methods: We interviewed 218 adult patients with bacteriologically confirmed pulmonary tuberculosis. Information on direct
(out-of-pocket expenses) and indirect (hours lost) costs, loss in income and costs with extra help were gathered through a
questionnaire. Healthcare system additional costs due to supervision of pill-intake were calculated considering staff salaries.
Effectiveness was measured by treatment completion rate. The ICER of DOT compared to self-administered therapy (SAT)
was calculated.
Principal Findings: DOT increased costs during the treatment phase, while SAT increased costs in the pre-diagnostic phase,
for both the patient and the health system. Treatment completion rates were 71% in SAT facilities and 79% in DOT facilities.
Costs per completed treatment were US$ 194 for patients and U$ 189 for the health system in SAT facilities, compared to
US$ 336 and US$ 726 in DOT facilities. The ICER was US$ 6,616 per completed DOT treatment compared to SAT.
Conclusions: Costs incurred by TB patients are high in Rio de Janeiro, especially for those under DOT. The DOT strategy
doubles patients’ costs and increases by fourfold the health system costs per completed treatment. The additional costs for
DOT may be one of the contributing factors to the completion rates below the targeted 85% recommended by WHO.
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Introduction
The burden of tuberculosis (TB) affects mainly the poor, to
whom the costs of accessing TB diagnosis and treatment may
represent a significant burden [1]. Brazil is ranked 14
th of the
twenty-two high burden countries that account for 80 percent of
the world’s TB burden, with 92,000 new cases each year [2].
Treatment is available free of charge in public healthcare units
since the sixties. In Rio de Janeiro, urban violence, poverty, social
inequity, and a complex healthcare system contributes to the high
incidence of TB, with 75/100,000 new cases reported yearly [3].
To address this problem more effectively, in July of 1999, the
Health Secretariat of Rio de Janeiro began to progressively
implement the directly observed therapy (DOT) strategy, initially
in six of the city’s 34 TB clinics [4]. In Rio de Janeiro, the DOT
program has been largely clinic-based, with treatment provided in
municipal health centers. In clinics where DOT is offered, all
patients are treated under supervision. During the intensive phase
(first two months), treatment is usually supervised at least three
times weekly, ideally five times weekly, followed by the
continuation phase (remaining four months), with supervision
twice weekly.
In Brazil, as in many other countries, the pathway to TB care is
characterized by several and repeated visits to different healthcare
providers, which are associated with both system and patient
delays [5]–[7]. Although public health services are, in theory,
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substantial portion of the costs still fall on the patients and their
families. A thorough understanding of the costs associated with TB
diagnosis and treatment is important to develop interventions to
reduce that economic burden on patients. Several studies have
assessed the patient and household costs of TB and the cost-
effectiveness of alternative TB treatment strategies around the
world [8]–[13], but these did not consider patient and health
system perspectives together. In this study, our primary objective
was to analyze the costs of care for tuberculosis patients
undergoing treatment in facilities using the DOT and facilities
providing only self-administered therapy (SAT) in Rio de Janeiro
State (RJ), Brazil. In addition, the extra costs of treatment
supervision to the patient and the health system were estimated to
calculate the incremental cost-effectiveness ratio (ICER) of the
DOT strategy per completed treatment.
Methods
Ethics Statement
The study was approved by the ethical committee of Gama
Filho University and the Brazilian National Ethical Committee
(CONEP, #235/2007). All interviewed patients gave written
informed consent.
Setting
In the RJ, a system for registering cases, a reliable supply of high
quality medications with fixed-dose combinations and access to
sputum smear microscopy have been in place for decades.
Diagnosis and treatment of TB is free of charge. However,
DOT has been introduced only recently in some health facilities,
with progressive expansion. Supervised treatment is mandatory in
clinics where DOT is implemented. Patients on SAT treatment
come once monthly for follow up visit and pill collection for the
entire month, while patients under DOT come in variable
frequencies, depending on the clinics (see extrapolation of costs).
Twenty-one health facilities in six TB high burden counties of RJ
were selected by convenience (suggested by state and municipal
TB control program coordinators), of which 12 used DOT for all
patients and 9 offered only SAT.
Patients
Eligible patients had bacteriologically confirmed pulmonary TB
(positive sputum smear and/or culture) with or without concom-
itant extra-pulmonary involvement, were aged 18 years or older
and were being treated at the selected health facility. Patients were
recruited from April 2007 to May 2008, after they had completed
approximately two months of treatment (from the 5th to the 11th
week of treatment). This time point was chosen since it was
considered the best compromise between more reliable recall of
costs incurred in the pre-diagnostic period while giving the patient
sufficient time of treatment to report on costs incurred during
treatment. All the patients were approached for the interview
while waiting for follow-up visits in the different health centers.
Overview of the Patient Cost Questionnaire
A standardized questionnaire was used to collect details
regarding all costs incurred by the TB patients and their families
for each care-seeking episode during the entire period of the
patient’s TB illness, from the onset of symptoms until the date of
interview. Information about direct and indirect costs was
gathered. Direct costs were defined as out-of-pocket expenditures,
including transportation fees, consultation fees, non-TB laboratory
tests, non-TB medication (vitamins, antibiotics, cough syrups and
others) and food. TB tests and drugs are offered free of charge in
all clinics. Indirect costs were defined as any time lost due to TB
illness, including travel time, consultation time, hospitalization,
and absenteeism from work. The patient’s time and that of his/her
family was ascertained. Family time was estimated from the
proportion of outpatient visits where a family member escorted the
patient, and the proportion of days a family member stayed or
visited a patient during his hospitalization.
The number of hours lost were multiplied by the hourly wage in
Brazil. The estimated hourly wage was 1.31 American dollars
(US$), based on the Brazilian annual minimum wage in 2008,
divided by the assumed number of annual hours of work based on
a 44 weekly hours of work contract (2,288 hours/year). Help with
daily tasks was also registered, whether paid (included as direct
costs) or not (included as indirect costs). All out-of-pocket
expenditures were recorded using the local currency and
converted into US$ considering the exchange rate at the time of
the interviews (US$1=1.80 Reais), based on the currency
exchange rates in 2008. Costs are presented according to the
period: pre-diagnosis costs were those since the beginning of
symptoms to the first confirmatory sputum test and post-diagnosis
were those incurred during the treatment phase.
General information regarding the patients’ household, em-
ployment, and income was also obtained. In addition, patients
were asked if their income and their family income decreased after
the onset of symptoms, and if the reduction was associated to the
illness. The final section of the questionnaire included any
additional expenditures or time lost by the patient and their
family.
Other important information gathered were the interval from
the onset of TB related symptoms until the patient first visited any
health facility, including pharmacies or alternative healers (patient
delay) and the interval between the patient’s first visit to a health
facility until the date the patient was officially diagnosed with TB
(health system delay).
The frequency and costs related to each medical follow-up and
DOT visit were collected separately, since patients typically came
monthly for medical follow-up visits, but came three times a week
for pill-collection and intake visits. The average time spent and
out-of-pocket expenditures were ascertained for the two types of
visits from the start of out-patient treatment until the date of
interview. These average costs were extrapolated to the projected
total number of DOT and follow-up visits throughout the entire
duration of the patient’s TB treatment, which was assumed to be 6
months, with the frequency of 5 times weekly during the intensive
phase and twice weekly during the continuation phase. Direct
costs were also ascertained for any extra help received due to
illness, including expenses due to help received before or after
diagnosis, as well as any extra monthly purchases due to the TB
illness.
Health Facility Costs
Healthcare system additional costs for DOT were calculated
based on salary of staff responsible for direct observation of
treatment. In RJ, the observation of pill intake is usually done by a
nurse or a nurse aid under the supervision of a nurse. In public
health facilities, staff with University degrees has equivalent
salaries and carrier plans. Since TB diagnosis and treatment had
already been available for decades in the municipal health centers
and health posts and supervision of treatment is done during the
usual opening hours of these healthcare units, with no additional
infrastructure needs, we assumed that all costs would be similar in
DOT and SAT facilities, except for human resources.
Cost-Effectiveness of DOT
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in each facility. The cost of each DOT (pill collection) visit was
estimated to be a third of the cost of a patient visit, based on the
relative times reported by patients for DOT and medical follow-up
visits, and on previous experience [13].
For hospitalization costs and average length of stay, information
was gathered in the Ministry of Health online database (available at
http://www2.datasus.gov.br/DATASUS/index.php?area=0202).
The mean length of hospitalization is 21.9 days, with a
reimbursement value of US$ 458.13.
Cost-effectiveness analysis
The measure of effectiveness was treatment completion rate,
since not all patients completing treatment have a bacteriological
confirmation of cure. For cost-effectiveness analysis, the incre-
mental cost-effectiveness ratio (ICER) was calculated dividing the
costs difference in DOT and SAT facilities by the completion rate
difference among interviewed patients under DOT and SAT.
Data Entry and Statistical Analysis
Data was double-entered into a database created in
Microsoft Access 2000 (Microsoft Inc., Virginia, USA). The
data was cleaned, any discrepancies were checked against the
original questionnaires and the accuracy of data entry was
verified. Data analysis was performed using SAS (SAS Institute
Inc., North Carolina, USA) by obtaining frequencies, means
and standard deviation (SD) or median and interquartile
ranges (IQR) when appropriate for patient characteristics and
cost variables. For health facilities, average costs and weighted
means were calculated. Differences in means where evaluated
using T tests, differences in medians were evaluated using the
Mann–Whitney U test and difference in proportions were
analyzed using the chi-square test. Costs were extrapolated for
the total number of new cases registered yearly in Rio de
Janeiro state (15,000).
Sensitivity Analyses
Sensitivity analyses were performed to explore the degree of
uncertainty of the treatment outcomes, the costs of follow-up and
pill-collection visits, the costs of hospitalization and the frequency
of weekly pill-collection visits. The total staff cost values varied
from 25% to twice the costs of the base case. The frequencies of
pill-collection visits ranged from the most frequently observed of
60 (corresponding to three visits weekly during the intensive phase
and twice weekly visits during the continuation phase) to 120 (five
weekly visits during the entire treatment) total visits. Hospitaliza-
tion costs varied with the length of stay and with the difference in
hospitalization rates.
Table 1. Characteristics of 218 patients interviewed in Rio de
Janeiro state, Brazil, according to the treatment strategy.
DOT N( % ) SAT N( % ) Pvalue
Sex
Female 42 (36.5) 37 (35.9) 0.93
Male 73 (63.5) 66 (64.1)
Age
,35 55 (47.8) 59 (57.3) 0.45
$35 60 (52.2) 44 (42.7)
Schooling
None 16 (13.9) 13 (12.6) 0.16
Primary 57 (49.6) 46 (44.6)
Unfinished High School 6 (5.2) 15 (14.6)
Finished High School 31 (27.0) 22 (21.4)
University 5 (4.3) 7 (6.8)
Household size
Lives alone 13 (11.3) 12 (11.7) 0.98
2 to 4 75 (65.2) 68 (66.0)
.5 27 (23.5) 23 (22.3)
Monthly income (US$)*
, $55 68 (59.1) 64 (62.1) 0.68
55–222 27 (23.5) 24 (23.3)
223–444 7 (6.1) 8 (7.8)
.444 13 (11.3) 7 (6.8)
Household monthly income (US$)*
, $55 29 (25.2) 28 (27.2) 0.27
55–222 30 (26.1) 35 (34.0)
223–444 21 (18.3) 20 (19.4)
.444 35 (30.4) 19 (19.4)
Employment status
Employed 60 (52.2) 58 (56.3) 0.42
Student 9 (7.8) 3 (2.9)
Unemployed 38 (33.0) 33 (32.1)
Retired 8 (7.0) 9 (8.7)
Co-morbidities
No 75 (65.2) 70 (67.0) 0.66
Yes 40 (34.8) 33 (32.0)
Type of first searched facility
Public Primary Care Unit 31 (27.0) 39 (37.9) 0.29
Pharmacy 12 (10.4) 9 (8.7)
Hospital 64 (55.6) 44 (42.7)
Private Clinic 7 (6.1) 10 (9.7)
Others 1 (0.9) 1 (1.0)
Time to reach healthcare unit
0–20 min 44 (38.3) 19 (18.4) ,0.01
21–40 min 28 (24.4) 21 (20.4)
.40 min 43 (37.4) 63 (61.2)
Health Insurance
No 94 (81.7) 90 (87.4) 0.25
Yes 21 (18.3) 12 (16.2)
Hospitalization
No 97 (84.4) 92 (89.3) 0.28
DOT N( % ) SAT N( % ) Pvalue
Yes 18 (15.6) 11 (10.7)
History of previous TB treatment
New case 95 (82.6) 92 (89.3) 0.16
Retreatment 20 (17.4) 11 (10.7)
N= number of patients in each category.
SAT=self-administered therapy.
DOT=directly observed therapy.
doi:10.1371/journal.pone.0014014.t001
Table 1. Continued.
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DOT (N=115) SAT (N=103)
n Mean cost (SD) n Mean cost (SD) P value
Delay in diagnosis (in days)
Patient delay - 64.3 (114.4) days - 88.9 (219.3) days 0.31
System delay - 36.4 (56.0) days - 52.5 (105.3) days 0.17
Before diagnosis
Direct
Transport 92 11.0 (14.7) 82 12.7 (14.9) 0.42
Consultation fees 10 2.2 (10.1) 16 7.1 (23.2) 0.05
Complementary exams 11 3.1 (10.3) 27 6.9 (19.3) 0.08
Non-TB medication 48 10.7 (22.7) 44 16.5 (30.4) 0.11
Food 43 2.1 (3.4) 50 3.1 (7.2) 0.16
Sub-total 102 29.1 (37.8) 103 46.3 (61.2) 0.11
Indirect
Value of time on trips to clinic and absenteeism 115 39.5 (180.6) 101 30.1 (132.4) 0.37
Value of family time escorting patient and absenteeism 64 5.6 (21.8) 72 3.1 (4.8) 0.4
Sub-total 115 45.1 (183.6) 103 33.2 (132.5) 0.11
Total before diagnosis 115 74.2 (187.5) 103 79.5 (146) 0.38
After diagnosis
Direct
Pill collection/follow-up visits 115 115.9 (371) 103 37.3 (55.2) 0.05
Indirect
Value of time for clinic visits and absenteeism 109 76.9 (141.4) 100 33.9 (33.8) ,0.01
Value of family time lost for clinic visits and absenteeism 74 37.1 (188.4) 57 16.7 (31.9) 0.03
Sub-total 115 114 (326.7) 103 50.6 (57.4)
Total after diagnosis 115 229.9 (494.3) 103 87.9 (79.6) ,0.01
Hospitalization costs
Direct 18 5.6 (30.2) 11 15.0 (131.7) 0.48
Indirect 18 26.7 (104.3) 11 11.6 (48.9) 0.08
Total patient costs
Total direct 108 150.6 (374.1) 103 98.6 (155.4) 0.78
Total indirect 115 185.8 (389) 103 95.4 (124.4) ,0.01
Total cost 115 336.4 (539.7) 103 194 (199) ,0.01
SAT=self-administered therapy; DOT=directly observed therapy. N=Number of people in each category; n= Number of people who reported any cost (mean values
include those patients who reported costs zero). US$1.00=R$1.80.
doi:10.1371/journal.pone.0014014.t002
Table 3. Patient costs according to outcome in DOT facilities.
Outcome %
Patient delay
(days)
System delay
(days)
Pre-diagnosis
period (US$)
Hospitalization
(US$)
Post-diagnosis
period (US$/month) Total (US$)
Completed (n=91) 79.1% 51.6 (74.2) 36.1 (55.9) 111.4 (515.1) 153.4 (526.8) 36.8 (38.5) 485.5 (764.3)
Default (n=20) 13.4% 126.8 (217.2) 31.8 (44.8) 48.7 (47.7 279.6 (794) 32.6 (20.5) 523.7 (745.4)
Failure (n=4) 3.5% 39.4 (43.0) 66.8 (106.8) 16.8 (14.6) 0 (0) 25.9 (10.4) 172.4 (67.5)
Death (n=0) 0 (0%) - - - - - -
US$1.00=R$1.80.
doi:10.1371/journal.pone.0014014.t003
Cost-Effectiveness of DOT
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Overall patient costs
A total of 218 patients were interviewed, 103 (47%) under SAT
and 115 (53%) under DOT. Their characteristics were similar,
except for time to reach the healthcare unit from home, which was
longer for SAT patients, as displayed in Table 1. Mean cost per
patient was US$ 336 (SD=540) for patients under DOT and US$
194 (SD=311), for patients under SAT, p=,0.01 (Table 2).
Considering an incidence of 15,000 new cases per year in Rio de
Janeiro, the DOT strategy accounted for an extra US$ 2,135,000
(95% CI=US$ 1,245,000-US$ 3,000,000) annual cost for patients
and their families when compared to the SAT, out of which 50%
was from indirect (lost wages or lost opportunity) costs.
Hospitalization and female gender were associated with higher
costs, regardless of the type of treatment strategy. Twenty-nine
(13.3%) patients were hospitalized at some point for a median time
of 7 days (IQR=2–20) and a mean time of 20.8 days. Patients
who were hospitalized had a mean cost of US$ 426 (SD 622) as
compared to US$ 235 (SD 398, p,0.01) for those who were not
hospitalized. Women had a mean cost of US$ 354 (SD 630) versus
US$ 214 (SD 269) for male, p=0.02.
Expenditures resulted mainly from transportation fees and from
medication for patients under DOT as well as those under SAT
(Table 2). DOT increased costs during the treatment phase, due to
increased indirect costs, while patients under SAT had higher costs
in the pre-diagnostic phase. Although not statistically significant,
total time to diagnosis was 40% longer in SAT facilities (Table 2).
For patients under DOT, factors associated with higher costs were
living alone, unemployment and hospitalization (data not shown).
For those under SAT, factors associated with higher costs were
older age, co-morbidities, hospitalization and history of previous
treatment (data not shown).
Approximately 35% of patients reported that their income
decreased, most (75%) because of TB. Extra help was needed by
102 (47%) patients, who incurred a total of US$ 8,821, exclusively
for indirect costs of time spent by family or friends helping these
patients.
Overall health system costs
The average health system cost per follow up visit was estimated
to be US$ 22.7 in DOT facilities and US$ 22.2 in SAT facilities.
The cost per DOT/pill-collecting visit was estimated to be US$
7.56. Extrapolating for a six-month TB treatment regimen, the
Table 4. Patient costs according to outcome in non-DOT facilities.
Outcome %
Patient delay
(days)
System delay
(days)
Pre-diagnosis
period (US$)
Hospitalization
(US$)
Post-diagnosis
period (US$/
month) Total (US$)
Completed (n=73) 70.9% 94.5 (248.9) 41.2 (50.3) 72.8 (86.8) 82.5 (349.9) 14.8 (9.6) 244.1 (374.4)
Default (n=26) 25.2% 70.0 (127.9) 59.1 (172.3) 52.3 (63.2) 68.1 (227.5) 11.8 (11.2) 191.2 (257.8)
Failure (n=3) 2.9% 27.5 (28.4) 58.0 (8.5) 82.5 (62.9) 0 (0) 7.9 (3.1) 129.7 (81.3))
Death (n=1) 1 (1%) 225.0 (190.9) 364.5 (51.6) 241.3 (327.8) 0 (0) 19.3 (19.1) 357.1 (443.7)
US$1.00=R$1.80.
doi:10.1371/journal.pone.0014014.t004
Figure 1. Incremental Cost-Effectiveness Ratio (ICER) according to different treatment completion rates in DOT facilities. The
incremental cost-effectiveness ratio was calculated according to an increasing treatment completion rate in treatment facilities offering DOT. The red
line represents the ICER taking into account only the costs to the health system.
doi:10.1371/journal.pone.0014014.g001
Cost-Effectiveness of DOT
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726 and US$ 189 for the SAT strategy.
Treatment outcomes
Among the 218 interviewed patients, 164 (75%) completed
treatment, 46 (21%) defaulted, 7 (3%) failed and 1 died (0.5%).
Outcomes according to treatment strategy are displayed in
Tables 3 and 4. Completion rates were higher in DOT facilities,
although this was not statistically significant [79% (72%;86%)
versus 71% (62%;80%), p=0.21].
Costs per case completing treatment
The average cost-effectiveness ratio for the SAT strategy was
calculated to be US$ 266 per completed treatment and US$ 919
per completed treatment for the DOT strategy. From the health
system perspective, the ICER of the DOT strategy compared to
the SAT strategy was US$ 6,616 per patient completing treatment.
From the patient perspective, the ICER was US$ 1,780 per patient
completing treatment. Varying the difference in treatment
completion rates from 1% to 25%, the incremental cost-
effectiveness ratio increased from US$ 3,554 to US$ 47,744 from
the health system perspective and from US$ 742 to U$ 11,140,
from the patients’ perspective (Figure 1 and Table 5). Other
sensitivity analysis results are displayed in Table 5.
Discussion
In the present study, a high financial burden was identified
among patients with pulmonary TB. One third of patients
reported a reduction in income, mostly due to TB disease. Lost
hours of work for diagnosis and supervision of treatment were the
main source of costs. Hospitalization was associated with a
significant increase in costs, a finding already reported in other
countries [13]. Efforts for an earlier diagnosis and prevention of
complicated and resistant forms of TB would likely reduce costs of
the disease by reducing the need for hospitalization.
Unlike previous findings in other countries [13], women
incurred in higher costs. Other patients’ socio-demographic
Table 5. Sensitivity analyses for varying differences of outcomes, length and rates of hospitalization, staff salaries and frequency of
treatment supervision.
Health system perspective ICER (US$/patient
completing treatment)
Patient’s perspective ICER (US$/patient
completing treatment)
Percentage of difference in treatment completion rates
Minimum (1%) US$ 47,744/pct US$ 14,240/pct
Base case (8%) US$ 6,616/pct US$ 1,780/pct
Maximum (25%) US$ 3,554/pct US$ 949/pct
Length of hospitalization (days)
225% - US$ 1,762/pct
Base case (21 days) - US$ 1,780/pct
25% - US$ 1,869/pct
50% - US$ 1,886/pct
100% - US$ 1,923/pct
200% - US$ 1,994/pct
Percentage of difference in hospitalization rates
25% US$ 6,899/pct -
Base case 0% US$ 6,616/pct -
5% US$ 6,335/pct -
10% US$ 6,053/pct -
15% US$ 5,771/pct -
Staff salary
275% US$ 1,654/pct -
250% US$ 3,308/pct -
225% US$ 4,965/pct -
Base case US$ 6,616/pct -
100% US$ 15,555/pct -
Total number of pill-collection visits
60 visits (3 weekly visits x 2 mo +2 weekly visits x 4 mo) US$ 5,313/pct US$ 650/pct
72 visits (3 weekly visits x 6 mo) – base case US$ 6,616/pct US$ 1,780/pct
88 visits (5 weekly visits x 2 mo and 3 weekly visits x 4 mo) US$ 10,528/pct US$ 2,728/pct
120 visits (5 weekly visits for 6 mo) US$ 12,390/pct US$ 3,474/pct
ICER=Incremental Cost-Effectiveness Ratio.
pct=patient completing treatment.
US$1.00=R$1.80.
doi:10.1371/journal.pone.0014014.t005
Cost-Effectiveness of DOT
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family income and level of instruction may have been missed
because the hourly wage was calculated based on minimum wage
rather than on declared family income. On the other hand, costs
may have been overestimated because indirect costs were taken
into account even for unemployed persons.
DOT was associated with the highest increase in costs, mostly
from time lost for collection/observation of pill intake, despite the
longer travel time to achieve the health facility taken by patients
treated under the SAT strategy. Mohan et al. [14] used a different
method to value the patients’ indirect costs for pill-collection visits
and found that they doubled. Using a more detailed approach, we
confirmed these data, but we also captured substantial increase of
direct costs.
Treatment completion rates were higher for patients under
DOT, although this was not statistically significant. The
effectiveness of DOT is consistent with the official RJ program-
matic data [14], [15]. However, the overall effectiveness of TB
treatment in RJ is 61%, but 19% of outcomes are unknown, thus
we believe our data to be a more reliable representation of the
overall effectiveness. The additional cost of DOT for patients and
their families is substantial, and may be contributing, in Rio de
Janeiro, to the treatment completion rates below the targeted 85%
recommended by WHO. Despite a reported increase in
effectiveness in some settings [14], [16], [17] in poor-resource
countries, DOT may be unaffordable, at least for the poorest.
Because of the modest increase in the treatment completion rate
with DOT, the ICER was high: US$ 6,616 for the health system
and US$ 1,780 for the patient. Sensitivity analyses showed that in
varying scenarios, ICER for patients would remain high. The
variable with the highest impact in ICER for patients was the total
number of pill collection visits, corresponding to a frequency not
considered as DOT by the WHO. Conversely, the variable with
the smallest impact in the ICER for patients was different lengths
of hospitalization. This is a reflection of the small percentage of
hospitalization (13%) yielding a modest average indirect cost due
to hospitalization. Oddly, the present sample had a higher rate of
hospitalization for DOT patients. Nevertheless, we performed a
sensitivity analysis assuming that it would be lower. The variation
in the ICER was small because the total amount of reimbursement
for hospitalization of each TB patient is undervalued.
The present study has a few limitations. First, economic
assessment in health is only one of the many tools for decision
making. Equity, ethics, resource availability and willingness to pay,
patients’ preferences and quality of life are other important aspects
to be considered. In addition, the current analysis does not take
into account the secondary benefits of treating one patient, such as
diminished transmission, effects on MDR prevalence and number
of deaths, thus underestimating the costs of SAT. Conversely,
opportunity costs regarding human resources allocated for
treatment supervision were not accounted for, thus underestimat-
ing DOT costs. In addition, we did not estimate the costs
associated with the implementation of DOT, such as training,
previously reported in the city of Rio de Janeiro [14]. Finally, we
interviewed patients on their 2
nd month of treatment, those who
defaulted before the interview were not captured in the analysis.
This may have hampered the effectiveness analysis.
Despite these limitations, this study clearly shows that a
significant proportion of the additional costs for DOT fall on the
patient, and that must be acknowledged to achieve a more
effective TB control strategy.
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